NKTR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
10.1M
-6.7%
10.9M
-50.2%
21.8M
+85.0%
11.8M
+5.5%
11.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
10.1M
-6.7%
10.9M
-50.2%
21.8M
+85.0%
11.8M
+5.5%
11.2M
Operating Expenses
52.5M
+5.1%
49.9M
+0.9%
49.5M
+13.8%
43.5M
-8.3%
47.4M
R&D
39.1M
+9.7%
35.7M
+20.1%
29.7M
+9.0%
27.3M
-8.8%
29.9M
SG&A
12.8M
-5.0%
13.4M
+20.2%
11.2M
-30.4%
16.1M
-5.9%
17.1M
Operating Income
-42341000
-8.4%
-39054000
-41.2%
-27665000
+12.7%
-31672000
+12.6%
-36230000
EBITDA
-41607000
-9.2%
-38107000
-101.6%
-18900000
+39.7%
-31336000
+11.9%
-35569000
Net Income
-40622000
+9.5%
-44904000
-24.5%
-36079000
-1.6%
-35522000
+14.6%
-41593000
EPS (Basic)
$-1.23
+32.4%
$-1.82
-2.8%
$-1.77
+5.3%
$-1.87
+36.6%
$-2.95
EPS (Diluted)
$-1.23
+32.4%
$-1.82
-2.8%
$-1.77
+5.3%
$-1.87
+36.6%
$-2.95
Shares (Diluted)
33.1M
+33.6%
24.7M
+21.3%
20.4M
+7.6%
18.9M
+34.5%
14.1M
Nektar Therapeutics (NKTR) โ€” Financials